NGL Fine-Chem Ltd.

3,206

268.4 (9.1%)stock indicator image for upward trend

As on July 3, 2026
SectorHealthcare
IndustryPharmaceuticals & Biotechnology
Basic IndustryPharmaceuticals
Market Cap1,977 Cr
P/E Ratio94.84
Dividend Yield0.01 %
Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

This image for unlock stock of the monthUnlock Stock of the Month

T&C*

Company Information


Market Insights
Open2,954.9
High3,260
NSE SymbolNGLFINE
Close3,206
Low2,954.9
BSE Symbol524774
Previous Years High/Low
1 Year High3,260
3 Year High3,260
5 Year High3,260
1 Year Low1,175.5
3 Year Low957
5 Year Low957

Technicals


IndicatorsValueSignal
5-DMA3,067.44Bullish
10-DMA3,067.54Bullish
20-DMA2,976.54Bullish
50-DMA2,659.38Bullish
100-DMA2,454.61Bullish
200-DMA1,948.14Bullish

Historical Performance


1 Year
164.9%
3 Years
70.8%
5 Years
N/A
10 Years
N/A

Shareholding Pattern


%

Values Analysis


Loading chart...

Profit & Loss

Below figures are in Rs. Crores


ParticularsMar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Net Sales3,6833,3872,7813,1752,580
Total Expenditure3,3352,8492,4312,4931,779
Other Income861415510780
Operating Profit434679405789881
Interest3318181922
Depreciation12511611310483
Profit Before Tax277544274666776
Consolidated Net Profit209412204498566
Adjusted EPS3467338192
Compounded Sales Growth
10 Years:19.2
5 Years:19.4
3 Years:3
TTM:1.7
Compounded Profit Growth
10 Years:0.7
5 Years:20.8
3 Years:-16
TTM:-12.7
Stock Price CAGR
10 Years:N/A
5 Years:N/A
3 Years:19.5
TTM:159.8
Return on Equity
10 Years:N/A
5 Years:91.6
3 Years:33
last year:33.8

Quarterly Results

Below figures are in Rs. Crores


ParticularsSep-2024Dec-2024Mar-2025Jul-2025Sep-2025
Sales1,70,7541,35,9361,28,5521,22,1891,05,161
Expenses63,04256,55752,45745,45934,856
Operating Profit1,07,71279,37976,09676,73070,304
OPM %63%58%59%63%67%
Other Income33,91231,75927,33324,87918,947
Interest77,78058,58459,24862,13753,713
Depreciation2,3451,6811,3851,2771,221
Profit Before Tax61,49850,87342,79638,19534,318
Tax %25%25%26%29%35%
Net Profit46,14938,15131,85727,29622,446
EPS in Rs8369585042

Balance Sheet

Below figures are in Rs. Crores


ParticularsMar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Share Capital3131313131
Total Reserves2,7932,5952,1952,0011,514
Long-Term Borrowings---------------
Total Non-Current Liabilities320636281112
Other Current Liabilities12240374461
Short Term Borrowings47831728423448
Total Liabilities4,3343,5552,8712,7692,074
Capital Work in Progress49745526364124
Long Term Loans & Advances4572585764
Currents Investments597536395287291
Short Term Loans and Advances325211150212140
Total Current Assets2,3542,1271,6271,7351,245
Total Assets4,3343,5552,8712,7692,074
Adjusted Book Value457425360329250
0%
Positive
(80 to 100)
Neutral
(60 to 79)
Negative
(0 to 59)
  • The stock has a high PE of 94.84, indicating expensive valuation or elevated growth expectations.
  • Over the last three years, the stock delivered a strong 3-year price CAGR of 19.5%, indicating sustained price appreciation.
  • The stock carries a high beta of 1.4, implying higher volatility and elevated risk.
  • In the last financial year, the company reported an EBITDA of ₹434 million, reflecting positive operating performance.
  • In the previous financial year, the company generated revenue of ₹3683 million, suggesting a mid-sized operation.

Investment Calculator


Investment Amount: ₹ 1000000
Current Value: ₹ 2606504.1
No. of Shares: 813 (Approx)
Performance:160.7%
P/L: ₹1606504.1
NIFTY Performance: -4.7%
1 day Top Gainers
SymbolChange%
SUMICHEM502.3(14%)
ZENSARTECH516.1(10%)
AEGISVOPAK257.43(10%)
ECLERX1488.8(7%)
KAYNES3333.8(6%)
1 Day Top Losers
SymbolChange%
GVT&D4401.5(-9%)
POWERINDIA31040(-8%)
ENRIN3281.5(-8%)
CGPOWER892.55(-7%)
UNIONBANK163.09(-7%)
THERMAX4607.5(-6%)
APARINDS14174(-6%)
TARIL336.75(-6%)

Top Performing Stocks from the same sector


Beta Drugs Ltd.

43.8%

2090.5

1 Month Performance

Bafna Pharmaceuticals Ltd.

41.8%

216.45

1 Month Performance

Ind-Swift Laboratories Ltd.

36.3%

214.16

1 Month Performance

Amanta Healthcare Ltd.

33.3%

163.09

1 Month Performance

Senores Pharmaceuticals Ltd.

32.2%

1381.9

1 Month Performance

Morepen Laboratories Ltd.

30.1%

59.07

1 Month Performance

Caplin Point Laboratories Ltd.

28.6%

2538.1

1 Month Performance

Panacea Biotec Ltd.

27.1%

551.2

1 Month Performance

Get Your Portfolio Reviewed

Stock of the Month
Stock of the Month